The ability to print human tissue is changing the way drug research is conducted today and opens the possibility of one-day printing replacement organs with the technology. CellInk saw an opportunity in making bioinks and started to produce a line of lower-priced printers as well in the hopes of expanding the marketing by lowering the cost of the technology. We spoke to Erik Gatenholm, CEO and co-founder of CellInk, about the technology, how its being used today, and how he expects applications for it to evolve.